<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157936</url>
  </required_header>
  <id_info>
    <org_study_id>HYPERURICEMIA 2010</org_study_id>
    <secondary_id>ALOPURINOL</secondary_id>
    <nct_id>NCT01157936</nct_id>
  </id_info>
  <brief_title>Hyperuricemia on Hypertension and Metabolic Syndrome</brief_title>
  <official_title>Effect of Hyperuricemia Treatment on Hypertension and Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Cardiologia Ignacio Chavez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the influence of hyperuricemia treatment compared
      with placebo on participants with high risk of hypertension and metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated consumption of high fructose corn syrup has lead to an increase of 30% of fructose
      intake since the last 20 years. Important data supporting this fact can be reflected on
      incidence and prevalence of Metabolic syndrome and hyperuricemia.

      A peculiar effect of fructose intake demonstrated in animal models is the development of
      elevated uric acid levels; also some studies have found a clear association between
      hyperuricemia as an important risk factor for hypertension, diabetes mellitus, chronic kidney
      disease and metabolic syndrome.

      Taking into account the existing evidence, our clinical research team presents this protocol
      as a way to evaluate the effect of uric acid treatment and its relation with Fructose
      consumption, metabolic syndrome parameters, hyperuricemia and risk of hypertension.

      Confirming evidence with clinical basis may be the initial strategy to create primary
      prevention programs to control this health problems affecting Mexican Population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of hyperuricemia treatment on systemic blood pressure</measure>
    <time_frame>14 weeks</time_frame>
    <description>participants will be randomized to a 4 week placebo versus alopurinol treatment followed by a wash out period. After crossover them, they will receive the complementary pharmacological intervention for another 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of hyperuricemia treatment on metabolic syndrome parameters</measure>
    <time_frame>14 weeks</time_frame>
    <description>baseline and final laboratory samples during pre and post crossover periods will include metabolic syndrome measurements (triglycerides, cholesterol, glucose and abdominal perimeter).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Systolic and Diastolic Blood Pressure Levels</condition>
  <condition>Uric Acid Levels</condition>
  <condition>Metabolic Syndrome Parameters</condition>
  <condition>Hepatic Enzymes</condition>
  <arm_group>
    <arm_group_label>Allopurinol treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>daily dosage</description>
    <arm_group_label>Allopurinol treatment</arm_group_label>
    <other_name>xanthine oxidase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>daily dosage</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults with blood pressure from 120/80 mmHg and less than 140/90 mmHg

          -  no pharmacological treatment for blood pressure control

        Exclusion Criteria:

          -  hypertension (more than 140/90mmHg)

          -  Diabetes Mellitus type 1 or 2

          -  Chronic kidney disease (MDRD less than 60)

          -  Hepatic Disease

          -  Malignancy

          -  Pregnancy

          -  patient receiving any medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Madero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cardiología Ignacio Chávez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Insituto Nacional de Cardiología Ignacio Chávez</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cardiologia Ignacio Chavez</investigator_affiliation>
    <investigator_full_name>Magdalena Madero</investigator_full_name>
    <investigator_title>Chief Nephrology Division</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

